Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G)

[Display omitted] To understand glucagon-like peptide-1 receptor agonist (GLP-1RA) use in patients with type 2 diabetes (T2D) in Japan. Characteristics of people receiving GLP-1RAs between 2016 and 2020 in the J-DREAMS database were investigated. Changes in HbA1c, body weight (BW), body mass index (BMI), and proportion reaching HbA1c targets were analysed in GLP-1RA-naïve patients 6–24 months after GLP-1RA initiation. The proportion of patients with GLP-1RA prescriptions increased from 3.6% to 9.6% during 2016–2020. Among GLP-1RA-naïve patients (n = 569), HbA1c reduced –‍0.6% (95% confidence interval [CI] –0.7, –0.5; –6 mmol/mol [95% CI –7, –5]) 6 months after treatment initiation and stabilised until 24 months (P